Gain Therapeutics, Inc. (GANX) earnings
GANX earnings moved a median of +0.72% by the close. Quarterly and annual GANX reports and results, each read against the price at its own news timestamp. Back to the GANX overview →
21 measured GANX earnings events.
Where these GANX earnings landedvs 19 measured GANX earnings reactions
| Middle 50% of GANX earnings reactions | -2.51% to +5.85% |
|---|---|
| Median reaction (to close) | +0.72% |
| Measured reactions | 19 |
Point-in-time · zero look-ahead
Half of the 19 GANX earnings events with a measured close landed between -2.51% and +5.85%; 58% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Gain Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +1.99% | +5.47% | |
| Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update | Press release | +2.09% | +15.73% | |
| Form 10-Q Gain Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +1.18% | +0.00% | |
| Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update | Press release | -2.70% | -1.62% | |
| Form 10-K Gain Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +2.10% | -3.68% | |
| Form 10-Q Gain Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -4.44% | — | |
| Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update | Press release | -5.47% | +1.72% | |
| Form 10-Q Gain Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +3.37% | +4.73% | |
| Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update | Press release | -2.25% | — | |
| Form 10-Q Gain Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | -1.08% | -2.16% | |
| Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update | Press release | -2.28% | -5.58% | |
| Form 10-K Gain Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | -0.49% | -6.44% | |
| Form 10-Q Gain Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | +5.07% | +11.14% | |
| Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update | Press release | +5.07% | +11.14% | |
| Form 10-Q Gain Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +3.06% | +0.14% | |
| Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update | Press release | +2.08% | +0.73% | |
| Form 10-Q Gain Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +6.31% | +6.94% | |
| Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update | Press release | -3.82% | -8.95% | |
| Form 10-K Gain Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | -0.65% | -2.87% | |
| Form 10-Q Gain Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | — | +6.23% | |
| Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update | Press release | — | +0.72% |
Keep exploring
More GANX: analyst actions → · SEC filings → · GANX overview →